684 / 1068
ACCORD 12/0405-Prodige-Trial
Inclusion criteria: cT3-4 Nx, ≤ 80 years , PS 0-1
R
RT 45* Gy
(@1.8Gy)
+
Capecitabine 1600 mg/m
2
/d 5d/w
T
M
E
Adjuvant
treatment
not
specified
RT
50*
Gy
(@ 2.0 Gy)
+
Capecitabine 1600 mg/m
2
/d 5d/w
Oxaliplatin
50 mg/m
2
weekly
T
M
E
Adjuvant
treatment
not
specified
(*15% increase in BED)
Primary endpoint: pCR (11% to 20%), 590 pts required